Insulin detemir in the treatment of type 1 and type 2 diabetes

  • Philips J
  • Scheen A
  • 7


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Insulin detemir is a soluble long-acting human insulin analogue at neutral pH with a unique mechanism of action. Following subcutaneous injection, insulin detemir binds to albumin via fatty acid chain, thereby providing slow absorption and a prolonged metabolic effect. Insulin detemir has a less variable pharmacokinetic profile than insulin suspension isophane or insulin ultralente. The use of insulin detemir can reduce the risk of hypoglycemia (especially nocturnal hypoglycemia) in type 1 and type 2 diabetic patients. However, overall glycemic control, as assessed by glycated hemoglobin, is only marginally and not significantly improved compared with usual insulin therapy. The weight gain commonly associated with insulin therapy is rather limited when insulin detemir is used. In our experience, this new insulin analogue is preferably administrated at bedtime but can be proposed twice a day (in the morning and either before the dinner or at bedtime). Detemir is a promising option for basal insulin therapy in type 1 or type 2 diabetic patients. © 2006 Dove Medical Press Limited. All rights reserved.

Author-supplied keywords

  • albumin
  • body weight disorder
  • clinical trial
  • drug absorption
  • drug dose regimen
  • drug efficacy
  • drug elimination
  • drug half life
  • drug indication
  • drug mechanism
  • drug protein binding
  • drug solubility
  • drug tolerability
  • fatty acid
  • glycemic control
  • glycosylated hemoglobin
  • hemoglobin A1c
  • human
  • human insulin
  • hypoglycemia
  • injection site reaction
  • insulin
  • insulin aspart
  • insulin dependent diabetes mellitus
  • insulin derivative
  • insulin detemir
  • insulin glargine
  • insulin treatment
  • insulin zinc suspension
  • isophane insulin
  • levemir
  • long acting drug
  • non insulin dependent diabetes mellitus
  • pharmacodynamics
  • review
  • risk reduction
  • short acting drug
  • weight gain

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • J.-C. Philips

  • A Scheen

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free